Premium
Cisplatin‐Rich Polyoxazoline–Poly(aspartic acid) Supramolecular Nanoparticles
Author(s) -
Zhang Peng,
Yuan Kangjun,
Li Cheng,
Zhang Xiaoke,
Wu Wei,
Jiang Xiqun
Publication year - 2017
Publication title -
macromolecular bioscience
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.924
H-Index - 105
eISSN - 1616-5195
pISSN - 1616-5187
DOI - 10.1002/mabi.201700206
Subject(s) - supramolecular chemistry , cisplatin , chemistry , nanoparticle , aspartic acid , cyclodextrin , combinatorial chemistry , stereochemistry , polymer chemistry , nanotechnology , organic chemistry , materials science , biochemistry , amino acid , crystal structure , chemotherapy , medicine , surgery
Cisplatin‐rich supramolecular nanoparticles are constructed through the supramolecular inclusion interaction between the admantyl (Ad)‐terminated poly(aspartic acid) (Ad‐P(Asp)) and the β‐cyclodextrin (β‐CD)‐terminated poly(2‐methyl‐2‐oxazoline). In the formation of the nanoparticles, the β‐CD/admantane inclusion complex integrates poly(2‐methyl‐2‐oxazoline) and poly(aspartic acid) chains to form pseudoblock copolymers, followed by the coordination between carboxyl groups in P(Asp) block and cisplatin. This coordination interaction drives the formation of nanoparticle and enables cisplatin incorporated into the nanoparticles. The spherical cisplatin‐rich supramolecular nanoparticles have 53% cisplatin‐loading content, good stability, and effective inhibition of the cell proliferation when it is tested in H22 cancer cells. Near‐infrared fluorescence imaging of tumor bearing mice reveals that the cisplatin‐rich nanoparticles can target the tumor in vivo effectively.